Summary.-Transplanted syngeneic osteosarcomas (induced by 32p in DA rats) grew significantly larger in DA rats receiving a simultaneous transplant of allogeneic osteosarcoma than in rats receiving syngeneic tumour only (P < 0.01). Two other malignant allogeneic tumours, and allogeneic spleen cells, did not alter the growth of the transplanted syngeneic osteosarcomas. When the allogeneic osteosarcoma was given 7 days before the syngeneic tumour, the reverse effect (retardation) occurred. When given 7 days after the syngeneic tumour cells, the effect on both syngeneic and allogeneic tumour growth was variable. Some possible reasons for these findings are discussed, and the argument is presented that immunological phenonema are involved in the reaction.
TRANSPLANTATION of allogeneic tumours has been demonstrated to suppress growth of spontaneous, viral or chemically induced tumours in a number of experimental animal studies (Sjogren, 1961; Klein, Sjogren and Klein, 1962; Britton, 1971; Usubuchi et al., 1972; Kobayashi et al., 1974) . We report here evidence that osteosarcoma allografts may, under certain conditions, actually enhance growth of a radiation-induced syngeneic osteosarcoma.
MATERIALS AND METHODS
Animals.-Male DA rats, shown to be inbred by cross skin grafting, and weighing approximately 250 g, were used.
Tumours.-The osteosarcomas were induced by 32p in DA and Wistar rats as previously described (Geddes-Dwyer et al., 1974) and maintained by serial transplantation in syngeneic animals. The 2 osteosarcomas in DA rats (designated F and G) were non-ossifying, very cellular and had a minimum of matrix. Tumour F was used from 20th to 55th transplant generation, and tumour G from 22nd to 50th. The Wistar osteosarcoma, used as allograft, was osteogenic and was of 22nd to 24th generation. Two other allogeneic tumours, namely a hepatoma (Buffalo rat-Morris hepatoma 5123C, transplant generation unknown) and a spontaneous non-epithelial anaplastic " mouth " tumour (Wistar rat, 1st to 9th transplant generations), were used in one series of experiments (Table III) . Tumour cells were separated enzymatically with pronase (2 mg/ml-Calbiochem) and DNAase (125 yg/ml Sigma (Table IV) . When the DA and Wistar cells were given in the same flank, 2 separate adjacent injections were used. All rats were killed after 21 days and the tumours dissected free from adherent tissues and weighed.
RESUILTS
Over the 3-year period during which these experiments were carried out, the injection of 3 x 106 osteosarcoma cells has resulted in a gradual reduction in the weight of resultant syngeneic tumour. This can be seen from Table I , in which the experiments are presented in chronological order. At present we are unable to explain this phenomenon. When the syngeneic tumour was given simultaneously with allogeneic osteosarcoma (on the same or opposite side, Tables I and II) , the syngeneic weight was significantly greater (ipsilateral P < 0 01, contralateral P < 0.05) than in animals bearing syngeneic tumours only. The other allogeneic tumours (Buffalo rat hepatoma and spontaneous Wistar mouth tumour) failed to alter syngeneic tumour weight appreciably (Table III) . Allogeneic spleen cells, given either simultaneously (Table II) or 7 days before the syngeneic osteosarcoma (Table IV) also had no effect on the syngeneic tumours.
Treatment of DA rats with allogeneic osteosarcoma 7 days before giving syngeneic tumour caused a significant reduction (P < 0-01) in syngeneic tumour weight when compared with the weights of syngeneic tumours in the untreated controls (Table IV) . This applied whether the tumour allograft cells were given within their matrix (allograft blocks) or as a suspension.
In the groups of rats receiving allogeneic tumour 7 days after the syngeneic tumour had been transplanted, increase in (Fig. 1) . In the groups where allogeneic tumour cells or blocks were given alone, at the same time or before the svngeneic tumour, histological sections showed complete rejection (Fig. 2) . The histological appearance of this boneforming osteosarcoma could not have been confused with the non-bone-forming DA svngeneic tumour (Fig. 3) .
DISCUSSION
In these experiments, simultaneous transplantation of syngeneic and allogeneic osteosarcomas resulted in an increase in weight of the syngeneic tumour rather than inhibition of growth as described by previous authors (Sjogren, 1961; Klein, Sjogren and Klein, 1962; Britton, 1971; Usubuchi ed al., 1972; Kobayashi et al., 1974) . This enhancement wa,s specific, in that it was produced by osteosarcoma allografts but not by allografts of spleen cells or of cells of 2 other malignant tumours (not osteosarcomas). Thi strongly suggest that immune phenomena were concerned, but the precise mechanism involved is not clear. Allografts have been shown previouslv to result in enhanced antibody responses to " weak" antigens present on allografts in chickens (Schierman and McBride, 1967; McBride and Schierman, 1973) . We have found evidence for the presence of a common tumour antigen on 32P-induced osteosarcoma (Geddes-Dwyer, Hersey and Cameron, in preparation) and it is therefore possible that the alloantigens have resulted in enhanced antibody production to this common tumour antigen by a similar " natural carrier" effect. A role for tumour antigen in the growthenhancing effect in our studies is suggested by the observation that allogeneic osteosarcoma resulted in significantly increased weight only when given in the presence of syngeneic tumour. When the allograft was given before the syngeneic tumour, the animals were protected against tumour growth. These results are consistent with the proposal that tumour enhancement is the result of immune complexes of antibody and tumour antigen rather than humoral antibody alone (Sjogren et al., 1971; Baldwin, Price and Robins, 1972) . Complexes of antibody and tumour antigen may also have been responsible for the prolonged life of allogeneic tumours in rats, only when given syngeneic tumour 7 days prior to allografting. It is possible that cell-mediated immunity directed against tumour antigens on the allograft surface was inhibited by complexes of tumour antigen and antibody already present at a significant level at the time of allografting.
Our findings of increased syngeneic tumour weight in the presence of allogeneic tumour given simultaneously, and to a less extent 7 days after the syngeneic tumour was transplanted, may have practical clinical implications. Immunization with allogeneic tumour cells has been carried out in several clinical immunotherapy trials (Mathe et al., 1972; Britton, 1971; Crowther et al., 1973; Romsdahl and Cox, 1973) . Our findings indicate that the use of tumour allografts for immunotherapy of human subjects should be treated with caution.
